Abstract
Ovarian cancer has the highest mortality rate in the world. Therefore, it is urgent but still challenging to develop an efficient circulating tumor cell (CTC) detection method to sensitively detect ovarian cancer. To address such issues, herein, for the first time, we present a novel CTC detection method for ovarian cancer cells by designing sensitive and rapid graphene-based biosensors. This graphene-based sensor, consisting of a cell pool and two electrodes, can be prepared by a conventional chip fabrication process. It demonstrates high-sensitivity detection even for several ovarian cancer cells by comparing the electrical signal before and after adding cell solution. Moreover, the graphene-based biosensors can perform rapid detection with good repeatability. This suggests that this novel method is possible to use for the early detection of ovarian cancer with very low CTC cell concentration. This work provides a novel and quick strategy to detect ovarian cancer and further judge or predict the risk of the transfer of ovarian cancer.
Highlights
Ovarian cancer has the highest mortality rate in the world
70% of patients are diagnosed when the cancer is in an advanced stage or with multiple site metastasis, with 55~75% of the patients suffering remission after clinical first-line treatment relapsed within 2 years [2], and the 10 year disease-free survival rate of patients with recurrence was less than 15% [3]
circulating tumor cell (CTC) detection is expected to be a potential method for the early detection of ovarian cancer
Summary
Ovarian cancer has the highest mortality rate in the world. The main reason for the high mortality rate is that about 75% of patients are in an advanced stage when they consult for medical advice, and only 25% of patients are found in the early stage [1]. Metastasis is the main cause of death in cancer patients. Solid tumors such as ovarian cancer, when the lesions can be found by conventional detection methods such as ultrasound examination or radiological examination, are often in an advanced stage, with poor treatment effect and high mortality. 70% of patients are diagnosed when the cancer is in an advanced stage or with multiple site metastasis, with 55~75% of the patients suffering remission after clinical first-line treatment relapsed within 2 years [2], and the 10 year disease-free survival rate of patients with recurrence was less than 15% [3]. Timely detection and treatment before cancer metastasis is the most important factor related to the prognosis of patients
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
